Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting

Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting

Source: 
Biopharma Reporter
snippet: 

Kite says a two-year retrospective analysis of the commercial manufacturing and supply of its CAR T therapy, called axicabtagene ciloleucel (Yescarta), shows a high manufacturing success rate and a reliable turnaround time.